Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

182.93 -0.15 (-0.08%)
Official Closing Price Updated: 5:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
71 72 Next >
AbbVie (ABBV) Q2 2023 Earnings Call Transcript
ABBV earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Why AbbVie Stock Is Jumping Today
Humira isn't the only story for AbbVie these days. 
Via The Motley Fool
AbbVie Stock Jumps After Q2 Earnings - Here's Why
AbbVie Inc (NYSE: ABBV) has reported Q2 adjusted EPS of $2.91, down 13.6% Y/Y, beating the consensus of $2.80. 
Via Benzinga
AbbVie Earnings, Revenue Fall Less Than Expected
Drug maker AbbVie reported Q2 profit and sales that fell from a year earlier but topped expectations. AbbVie stock rose. 
Via Investor's Business Daily
US Stocks Buckle Up For Solid Open On Meta's Earnings Boost, Fed Relief — But Analyst Advises Some 'Value-Style' Rebalancing
Stocks could be heading to a higher open on Thursday, as traders digest some positive earnings reports and look ahead to another batch of economic data. 
Via Benzinga
Check Out What Whales Are Doing With ABBV
Via Benzinga
Check Out What Whales Are Doing With ABBV
Via Benzinga
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Via Benzinga
Peering Into AbbVie's Recent Short Interest
Via Benzinga
AbbVie's Skyrizi Achieves Superiority Versus Amgen's Drug In Head-to-Head Study In Moderate Plaque Psoriasis
AbbVie Inc (NYSE: ABBV) announced that the British Journal of Dermatology published results from the head-to-head Phase 4 IMMpulse study that evaluated the efficacy and safety of Skyrizi (risankizumab)... 
Via Benzinga
Seven Humira Biosimilars: Increased Competition In Arthritis Drug Market Sparks Need For Reform Of Drug Pricing Intermediaries
Seven pharmaceutical companies recently launched their biosimilars of AbbVie Inc's (NYSE: ABBV) top-selling  
Via Benzinga
3 Stocks to Buy While They Are on Sale
These stocks might not remain as cheap as they are now for too much longer. 
Via The Motley Fool
Looking to Get Richer? These 2 Dividend Stocks Have Doubled in 5 Years
A pharmaceutical company and a health insurance company outperformed the S&P 500 and paid a dividend. 
Via The Motley Fool
Growing Competition in Hematology, Aesthetics Complicates AbbVie's Post-Humira Landscape, Analyst Says
William Blair has initiated coverage on AbbVie Inc (NYSE: ABBV) with a  
Via Benzinga
AbbVie Inc. (NYSE: ABBV) Highlighted for Surprising Price Action
Via Investor Brand Network
Benzinga's Top Ratings Upgrades, Downgrades For July 25, 2023
Via Benzinga
The 7 Best Dividend Stocks to Protect Your Portfolio From Global Chaos
With global events only rising in entropy, investors ought to consider these best dividend stocks for portfolio protection. 
Via InvestorPlace
Big Weeks Ahead For MedTech And Life Science Stocks
It’s a big week for earnings that may change the trajectory of the rally but more than likely will continue the rotation into different sectors. 
Via Talk Markets
Dow Jones Leads Weekly Gains As Tesla, Netflix Sell-Offs Dent Nasdaq; Big Banks Show Resilience To Volatility
Via Benzinga
3 High-Yield Dividend Stocks I Plan on Holding Forever
These stocks offer great yields but have even better underlying businesses. 
Via The Motley Fool
3 of the Best Dividend Stocks to Buy for Passive Income Growth
For investors looking to create a meaningful stream of passive income in retirement, these dividends stocks are great options. 
Via InvestorPlace
7 Fantastic Forever Stocks for Long-Term Lucrative Gains
These forever stocks to buy offer compelling bull cases for the long-haul, alongside spectacular upside potential. 
Via InvestorPlace
Top Yielding Dividend Aristocrats
Here are some of the top Dividend Aristocrats in 2023. 
Via Talk Markets
3 Biotech Stocks for Getting Rich in 2023
These 3 biotech stocks have seen stable or growing revenue this year. This makes them companies to keep on your watchlist. 
Via InvestorPlace
BeiGene's Brukinsa Positioned as Preferred BTK Inhibitor: Analyst Says Survey Supports Bullish View
Citi initiated coverage on BeiGene Ltd (NASDAQ: BGNE) with a price target of $275 and a B 
Via Benzinga
MoonLake's Potential Sale: Stock Price Up Fivefold Since Public Debut In 2022
MoonLake Immunotherapeutics (NASDAQ: MLTX) has reportedly engaged an investment bank as the Swiss company looks for a potential sale. The company focuses on developing antibody-derived treatments for... 
Via Benzinga
3 Dividend Stocks That Still Make Sense in 2023
Investors are still faced with an uncertain market which is favorable for these three dividend stocks regardless of what happens in the economy 
Via MarketBeat
Topics Economy
Exposures Economy
3 Dividend Growth Stocks to Buy and Hold
Where these dividends are going is even more important than where they've been. 
Via The Motley Fool
7 Spectacular High-Yield Dividend Stocks to Buy in July
These dividend yields could be hotter for investors than the temperatures this month. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2023
Via Benzinga
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
71 72 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.